Application of a Protocol of Personalized Medicine in Patients With Type 2 Diabetes Mellitus and Multiple Doses of Insulin in Routine Clinical Care

Summary

The goal of this observational study is to test a protocol of personalized medicine in routine clinical practice in people with type 2 diabetes (T2DM) treated with multiple dose insulin injections (MDI). The main question\[s\] it aims to answer are: • Are c-peptide titers and B-cell autoimmunity useful to help the decision of suspending prandial insulin in patients with T2DM treated with MDI? Participants will: * Wear a continuous glucose monitor for 10-14 days * Will be asked for a C-peptide and GAD antibody test (GADA) * Will stop prandial insulin and switch to other diabetes treatments if needed if c-peptide is \> 0.7 mmol/L and/or C-peptide is \> 0.3 mmol/L and GADA are negative * Will be followed-up by their GP in routine clinical practice * Will be assessed after 6 months (CGM, HbA1c, quality of life (QoL)

Eligibility

Inclusion Criteria:

* Type 2 diabetes treated with multiple dose insulin therapy

Exclusion Criteria:

* Gestation or planning gestation in the following 12 months
* Glucocorticoid use for an acute condition
* Transient insulinisationt (less than 6 months)
* Any condition that prevents the patient or their caregiver from following up for 6 months
* Severe mental illness
* Drug or alcohol abuse

Conditions3

Browse More Trials